Webinar Alert! Assessing the Use of Non-Human Primates in Translational Research Today Register Today!

Quantifying AAV Vector Shedding in Breast Milk: A Critical Safety Assessment for Postpartum Gene Therapy Patients

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Quantifying AAV Vector Shedding in Breast Milk: A Critical Safety Assessment for Postpartum Gene Therapy Patients

Quantifying AAV Vector Shedding in Breast Milk: A Key Safety Assessment for Postpartum Gene Therapy Patients

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

    What is the typical limit of quantification (LOQ) for AAV vector DNA in breast milk samples?

    A: Our GxP-compliant qPCR and ddPCR assays are validated to achieve a high degree of sensitivity suitable for regulatory submissions. The specific LOQ is established and customized for each vector construct and program’s requirements during method development and validation.

    How does sample matrix interference from breast milk affect assay performance?

    A: The high lipid and protein content of breast milk can inhibit PCR amplification. We employ validated nucleic acid extraction protocols specifically optimized to remove these inhibitors, ensuring high recovery rates and accurate quantification without compromising assay sensitivity or precision.

    Is it necessary to assess both vector DNA and transgene mRNA shedding?

    A: Regulatory guidance typically focuses on vector DNA shedding as the primary endpoint for biodistribution and transmission risk. However, assessing transgene mRNA via RT-qPCR can provide valuable data on vector activity and potential protein expression in non-target tissues, which may be requested for certain programs.

    What sample collection and storage protocols are recommended for maintaining vector stability?

    A: We provide sponsors with detailed collection kits and protocols. Samples should be collected into sterile containers with appropriate preservatives, immediately frozen, and maintained at ≤ -70°C during storage and shipment to ensure nucleic acid integrity upon arrival at our >100,000 sq ft facility.

Executive Summary

Assessing the potential for adeno-associated virus (AAV) vector shedding in breast milk is a required safety endpoint for gene therapies intended for women of childbearing potential. Franklin Biolabs provides validated, GxP-compliant quantitative PCR (qPCR) and droplet digital PCR (ddPCR) assays to precisely measure vector DNA copies in lactation samples. This analysis directly informs risk assessments for infant exposure, supports regulatory submissions, and is a key component of the comprehensive safety data package required to support a successful IND filing within an 18-24 month timeline.

A marketing fact sheet from Franklin Biolabs about the scientific benefits of Mauritian cynomolgus macaques for preclinical research, featuring a photo of the primates.

A stylized rendering of a DNA double helix on the left side of a light blue gradient background.

Regulatory Expectations for Lactation Shedding Studies

As AAV-based gene therapies advance into clinical evaluation for a wider range of indications, sponsors must address safety questions for specific patient populations, including postpartum individuals. Regulatory bodies require robust data to characterize the biodistribution profile of any investigational product. For therapies administered to women who may be lactating, quantifying vector presence in breast milk is a direct measure of potential infant exposure risk.

This analysis provides safety data that directly influences clinical trial design, patient informed consent, and eventual labeling language. A comprehensive understanding of vector shedding kinetics helps define any necessary precautions for treated mothers and their infants.

Quantitative Bioanalytical Methodologies

The accurate quantification of viral vector DNA in a complex biological matrix like breast milk demands highly sensitive and specific bioanalytical methods.

  • Quantitative PCR (qPCR): This is a well-established method for routine quantification, offering high throughput and a broad dynamic range for detecting vector DNA.

  • Droplet Digital PCR (ddPCR): For samples near the lower limit of quantification or where absolute copy number determination is needed without a standard curve, ddPCR provides enhanced precision and resistance to PCR inhibitors.

Our scientific team develops and validates custom assays for your specific AAV serotype and transgene cassette, ensuring the resulting data package is fit-for-purpose for regulatory review. The development of novel clinical candidates, such as those for familial hypercholesterolemia (PMID: 34258325), relies on a foundation of rigorous analytical characterization that defines the vector’s behavior in vivo. This includes a complete profile of non-target tissue biodistribution and shedding.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

Animal Welfare and Preclinical Study Design

Preclinical lactation studies, when scientifically justified, are conducted under rigorous animal welfare programs. Our approach adheres to the 3Rs (Replacement, Reduction, Refinement) to ensure the highest ethical standards and aligns with guidelines from bodies such as AAALAC and the USDA.

These preclinical models provide the initial data on shedding potential, informing the design and timing of sample collection in first-in-human clinical trials. By establishing a baseline understanding of vector clearance and distribution, we enable sponsors to build more efficient and targeted clinical safety monitoring plans.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities